In those with advanced/metastatic NSCLC with actionable mutations (n = 34), which included 29 EGFR-mutated patients, the ORR was 35% (19.7–53.5) with a median DOR of 9.5 months (95% CI, 3.3–NE) (56). This evidence concerns the gene EGFR and non-small cell lung carcinoma.